JPMorgan Chase & Co. Has $4.24 Million Stock Position in LifeStance Health Group, Inc. (NASDAQ:LFST)

JPMorgan Chase & Co. boosted its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 507.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,154 shares of the company's stock after buying an additional 480,518 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.15% of LifeStance Health Group worth $4,239,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LFST. Blue Trust Inc. raised its stake in shares of LifeStance Health Group by 124.4% during the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after acquiring an additional 2,122 shares in the last quarter. R Squared Ltd purchased a new stake in LifeStance Health Group in the fourth quarter valued at $80,000. Cibc World Markets Corp purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at about $96,000. Handelsbanken Fonder AB purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at about $128,000. Finally, Versor Investments LP purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at about $131,000. Institutional investors own 85.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. William Blair restated an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. Canaccord Genuity Group started coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price target for the company. Finally, KeyCorp started coverage on LifeStance Health Group in a research note on Tuesday, April 8th. They set an "overweight" rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.30.

Insider Buying and Selling

In other news, insider Lisa K. Miller sold 18,845 shares of LifeStance Health Group stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total value of $130,030.50. Following the completion of the sale, the insider now directly owns 339,810 shares of the company's stock, valued at approximately $2,344,689. This trade represents a 5.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.60% of the stock is owned by corporate insiders.

LifeStance Health Group Stock Performance

Shares of LFST stock traded up $0.04 during mid-day trading on Thursday, reaching $6.41. The stock had a trading volume of 125,039 shares, compared to its average volume of 1,609,450. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm has a market cap of $2.46 billion, a PE ratio of -24.63 and a beta of 1.30. LifeStance Health Group, Inc. has a one year low of $4.64 and a one year high of $8.61. The firm's 50 day simple moving average is $7.05 and its 200 day simple moving average is $7.31.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.